This is a standard, non-contentious annual meeting. Traders should note that the proposals are routine and are expected to pass with strong support, as is typical for management-backed votes. No significant market movement is anticipated from this filing.
Price Chart
Executive Summary
Oruka Therapeutics, Inc. (ORKA) has filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting, scheduled for June 2, 2026. The meeting will address the election of two Class II directors, the ratification of PricewaterhouseCoopers LLP as the independent auditor, and the advisory approval of executive compensation. This is a routine annual shareholder meeting with no activist involvement or contentious issues.
Key Facts
- The filing is a routine annual proxy statement for the 2026 shareholder meeting.
- Three proposals are on the agenda: election of two Class II directors (Lawrence Klein and Chris Martin), ratification of the independent auditor, and advisory approval of executive compensation.
- The meeting will be held virtually on June 2, 2026.
- The filing was made by the registrant (Oruka Therapeutics, Inc.), indicating it is a standard management proposal.
Financial Impact
No direct financial impact from the filing itself.
Risk Factors
- None identified from the filing itself.
- General market risk associated with the company's performance, which is not addressed in this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| DEFA14A Filing (Primary) | 0001213900-26-045169 |
| Document: 0001213900-26-045169-index-headers.html | 0001213900-26-045169 |
| Document: 0001213900-26-045169-index.html | 0001213900-26-045169 |
| Document: 0001213900-26-045169.txt | 0001213900-26-045169 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | Insider Cluster | $93.55 $89.93 | ▼ −3.87% | ▼ −6.44% | $84.38 (−9.80%) |
Sep 1, 2026 4w ago | Insider Cluster | $91.63 $91.65 | ▼ −0.02% | ▼ −0.98% | $84.38 (+7.91%) |
Aug 28, 2026 5w ago | EFFECT | $91.15 $92.51 | ▼ −1.50% | ▼ −1.39% | $84.38 (+7.42%) |
Aug 17, 2026 6w ago | Insider Cluster | $113.08 $101.82 | ▼ −9.96% | ▼ −9.76% | $84.38 (−25.38%) |
Aug 10, 2026 7w ago | Press Release | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 10, 2026 7w ago | 8-K | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Aug 9, 2026 7w ago | Institutional Cluster | $105.14 $112.66 | ▲ +7.15% | ▲ +7.20% | $84.38 (−19.75%) |
Jul 15, 2026 11w ago | Insider Cluster | $83.04 $91.95 | ▲ +10.73% | ▲ +12.40% | $84.38 (+1.61%) |
Jul 2, 2026 13w ago | Insider Cluster | $85.21 $88.27 | ▲ +3.59% | ▲ +2.66% | $84.38 (−0.97%) |
Jun 22, 2026 14w ago | Insider Cluster | $83.40 $92.49 | ▲ +10.90% | ▲ +9.89% | $84.38 (+1.18%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access